All Stories

  1. A novel intraperitoneal therapy for gastric cancer with DFP‐10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model

    Article • Cancer Medicine, October 2019, Wiley

    President Kiyoshi Eshima

  2. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model

    Article • Drug Design Development and Therapy, March 2018, Dove Medical Press

    President Kiyoshi Eshima

  3. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents

    Article • Drug Design Development and Therapy, June 2017, Dove Medical Press

    President Kiyoshi Eshima